Nanobiotix (NASDAQ:NBTX) Shares Down 4.7% – What’s Next?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) dropped 4.7% on Thursday . The company traded as low as $39.65 and last traded at $39.7250. 50,929 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 85,269 shares. The stock had previously closed at $41.67.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Leerink Partners raised their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Trading Down 3.0%

The company’s fifty day simple moving average is $39.72 and its 200-day simple moving average is $36.64.

Institutional Trading of Nanobiotix

A number of hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in shares of Nanobiotix in the 4th quarter valued at $220,000. Royal Bank of Canada grew its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.